Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2023 | Evolving landscape of urothelial cancer treatment: erdafitinib or enfortumab vedotin?

Yohann Loriot, MD, PhD, Gustave Roussy, Villejuif, France, discusses the evolving landscape of urothelial carcinoma management, touching on results from EV-301 (NCT03474107), as well as the use of erdafitinib in patients with advanced or metastatic disease. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.